Title: pharmacokinetic and bioavailability studies and analytical support with selected anticancer compounds in mice.period of performance: 4/28/17 - 4/27/2022
Ended Awarded Last action
- Contract number
- HHSN26100002
- Awardee
-
Mayo Clinic UEI Y2K4F9RPRRG7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $136,518
Award facts
- Opportunity
-
- N02CM6700011 Solicitation number
- Preclinical Pharmacokinetic and Pharmacology Evaluations of Agents Being Developed for Cancer Patients Award Notice · Posted Feb 5, 2016
- Preclinical Pharmacokinetic and Pharmacological Studies Being Developed for Cancer Patients Award Notice · Posted Oct 6, 2015
- Contract value 67% obligated
-
- $136,517.95 Current, with exercised options
- $204,622.95 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 5 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Rochester, MN 55905, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$30,672 | |
| Exercise an Option | $0 | |
| Other Administrative Action | $66,876 | |
| Other Administrative Action | $83,595 | |
| Original award | $16,719 |
About this award
This is a delivery order awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to Mayo Clinic, a large non-profit academic medical center. The five-year, $204,622.95 contract supports pharmacokinetic and bioavailability studies of selected anticancer compounds in mice, which will provide analytical support to the NCI's Experimental Therapeutics program. Mayo Clinic is conducting these preclinical evaluations under a larger $9.9 million multiple-award indefinite delivery/indefinite quantity (IDIQ) contract with the NCI, awarded in 2021. This IDIQ contract enables the NCI to efficiently access Mayo Clinic's cancer research and drug development expertise over multiple years. The current delivery order does not have a set-aside designation, reflecting Mayo Clinic's status as a large institution.
Quick answers
Who was awarded contract HHSN26100002?
HHSN26100002 was awarded to Mayo Clinic by National Cancer Institute (National Institutes of Health) on April 28, 2017.
How much is contract HHSN26100002 worth?
The government has obligated $136,518 on HHSN26100002. Its potential value, with all options, is $204,623.
Is contract HHSN26100002 an order under another contract?
Yes. HHSN26100002 is a delivery order under HHSN261201600024I, an indefinite delivery contract, on Pharmacokinetic and Pharmacology Evaluations for Cancer Patients.
Was contract HHSN26100002 competed?
The extent of competition for HHSN26100002 was full and open competition. The government received 5 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award